GOLSEEK-1
Tests whether a potent oral degrader added to R-CHOP raises cure rates in high-risk disease.
Builds on phase 1b data with high complete response rates; readout expected 2027-28.
Setting
Untreated high-risk LBCL (IPI 3-5): golcadomide + R-CHOP vs placebo + R-CHOP
Phase
Phase 3
Sponsor
BMS
Registry